Guide
Tirzepatide for Sleep Apnoea: An Approved Indication, Not an Off-Label Hope
This is one of the few areas where a GLP-1 carries an approval beyond weight and diabetes. SURMOUNT-OSA reported large reductions in the apnoea-hypopnoea index in adults
This is one of the few areas where a GLP-1 carries an approval beyond weight and diabetes. SURMOUNT-OSA reported large reductions in the apnoea-hypopnoea index in adults with obesity and moderate to severe obstructive sleep apnoea, and the indication followed.
What does the evidence actually show?
| Field | SURMOUNT-OSA |
|---|---|
| Population | Adults with obesity and moderate-to-severe OSA |
| Primary endpoint | Change in apnoea-hypopnoea index |
| Result | Large AHI reduction against placebo |
| Duration | 52 weeks |
| Regulatory outcome | An approved indication, not off-label use |
An approved indication for a condition many plans do cover is a different insurance argument from a weight-management request. Plans that exclude obesity drugs may still cover a therapy indicated for diagnosed sleep apnoea.
That does not make it automatic, and it does not mean a diagnosis can be manufactured to unlock coverage. It means that if you have diagnosed moderate-to-severe OSA, the indication exists and is worth raising with your prescriber.
It does not replace CPAP by default. The trial measured AHI reduction, not substitution for existing therapy, and that decision belongs with the clinician managing your apnoea.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does treatment cost while this is true?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is tirzepatide approved for sleep apnoea?
Yes. Following SURMOUNT-OSA, it carries an indication for moderate-to-severe obstructive sleep apnoea in adults with obesity.
Does it replace CPAP?
Not by default. The trial measured apnoea-hypopnoea index reduction, not substitution for existing therapy. That is a decision for the clinician managing your apnoea.
Does the indication help with insurance?
It can change the argument, because many plans cover sleep apnoea therapy while excluding obesity drugs. It is not automatic.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Ro Body vs Hims & HersComparisons
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- NexLife vs Ro BodyComparisons
- NexLife vs Hims & HersComparisons
- Mounjaro vs ZepboundPillar / Money
- Hims & Hers Tirzepatide ReviewProviders
Related coverage
- Tirzepatide Side Effects Week by Week: What the Trials Recorded
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Tirzepatide Plateau: Why Weight Loss Stalls and What the Data Says
- Tirzepatide and Prediabetes: The 176-Week Prevention Data
- Tirzepatide Price by Dose
- Tirzepatide Price Comparison by Provider
- What Tirzepatide Actually Costs at a Maintenance Dose: Five Ladders, Compared
- Compare Tirzepatide Providers Side by Side
GLP-1 Tirzepatide Rank. “Tirzepatide for Sleep Apnoea: An Approved Indication, Not an Off-Label Hope.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-sleep-apnea-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.